Back

The impact of obesity and diabetes on clinical and paraclinical characteristics of patients with dilated cardiomyopathy

18 May 2025 (15:40 - 17:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - comorbidities (2) Comorbidities HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Attila Frigy

George Emil Palade University of Medicine and Pharmacy, Targu Mures (Romania)

5 More presentations in this session

Presentation thumbnail
Dynapenia, sarcopenia, hydric alterations and body composition according to the type of heart failure
Doctor M. Hernandez Hernandez (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Investigation & management of hyponatremia in elderly heart failure cohort attending an ambulatory disease management service: a real world, single centre experience.
Ms L. O'connor (Dublin 9, IE)
Abstract Slides Video
Presentation thumbnail
Impact of type D personality and depressive symptoms on functional status and quality of life in worsening heart failure patients
Mr G. Guastamiglio (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Impact of diabetes mellitus on clinical characteristics, treatment patterns, and outcomes in heart failure patients: a retrospective multi-center, multi-ethnic cohort study
Doctor W. Ho (Kuching, MY)
Abstract Slides Video
Presentation thumbnail
The prognostic significance of micronutrient imbalance and malnutrition in patients with chronic heart failure
Doctor A. Chopanova (Ashgabat, TM)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - comorbidities (2)

The Event

Event poster

Heart Failure 2025

18 May 2025 15:40 CET
You may be interested in
thumbnail
Congress Presentation
Influence of metabolic comorbidities on dilated cardiomyopathy
thumbnail
Congress Presentation
The influence of cardiovascular risk-related comorbidities on the development of dilated cardiomyopathy
thumbnail
Congress Presentation
Characteristics, treatment and outcomes of obese vs non-obese dilated cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources